Screener
Rhythm Pharmaceuticals, Inc. RYTM Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $62,137 | $54,301 |
| Short-term investments | 278,488 | 334,648 |
| Accounts receivable, net | 34,192 | 26,081 |
| Inventory | 28,651 | 25,753 |
| Prepaid expenses and other current assets | 26,622 | 26,133 |
| Total current assets | 430,090 | 466,916 |
| Property and equipment, net | 1,065 | 1,104 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s accounts receivable?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported accounts receivable of $34.19M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s accounts receivable changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s accounts receivable increased by 91.8% year-over-year, from $17.83M to $34.19M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s accounts receivable?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s accounts receivable has grown at a 169.2% compound annual growth rate (CAGR), from $1.96M to $103.06M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude